The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for…
This action comes amid a surge in demand for GLP-1 receptor agonists for weight management, which has led some telehealth providers to offer compounded versions of semaglutide. The FDA has previously cautioned about the risks of compounded drugs, including potential impurities, incorrect dosing, and lack of sterility. For researchers and industry professionals, this news reinforces the importance of using verified, high- quality /tools/peptide-purity-analyzer research compounds /catalog from reputable suppliers like Volta Peptides, which offers a range of peptides for legitimate scientific study.
The FDA's letters also serve as a reminder that the line between approved drugs and research compounds is strictly enforced. Companies that blur this line risk regulatory action, which can disrupt supply chains and research timelines. Researchers should stay informed about regulatory changes and ensure their work complies with all applicable laws.
Telehealth companies have become a major channel for distributing compounded weight-loss drugs, often bypassing traditional pharmacy oversight. The FDA's letters target these companies specifically, demanding that they stop making claims that could mislead patients about the safety or efficacy of their products. This could lead to changes in how telehealth providers operate, potentially reducing access to compounded semaglutide for some patients.
---
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg /product/semaglutide-10mg | ≥98% | 10mg | $49.00 |
| BPC-157 5mg /product/bpc-157-5mg | ≥98% | 5mg | $34.00 |
| TB-500 5mg /product/tb-500-5mg | ≥98% | 5mg | $29.00 |
| BPC-157 10mg /product/bpc-157-10mg | ≥98% | 10mg | $44.00 |
Browse Full Catalog → /catalog
Semaglutide is a GLP-1 receptor agonist approved by the FDA under the brand names Ozempic and Wegovy for the treatment of type 2 diabetes and weight management. It works by mimicking a hormone that regulates appetite and blood sugar levels.
When used as prescribed under medical supervision, semaglutide has a well-established safety profile. However, compounded versions may not undergo the same quality controls, and the FDA has warned about potential risks including contamination and incorrect dosing. Always use FDA-approved products or research-grade compounds from verified suppliers.
Common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation. More serious risks include pancreatitis, gallbladder disease, and thyroid tumors. Patients should discuss these risks with their healthcare provider before starting treatment.
Peptides referenced: BPC-157, TB-500, Semaglutide, GLP-1.
Vendors referenced: Volta Peptides.
Related reading: Zepbound News: Why Setting Weight Loss Goals May Be Key to Success, Zepbound News: Why Setting Weight Loss Goals May Be Key to Success, FDA Cracks Down on Telehealth Claims for Compounded Weight-Loss Drugs, Rugiet enters longevity market with peptide therapy offerings.